Take a look at this article authored by our director team on the COVID-19 vaccine in pregnancy, here is a summarized abstract:
The study examined the impact of COVID-19 vaccination on pregnant individuals in Iran, focusing on the Sinopharm vaccine. Conducted from March 2021 to March 2022, it included 129,488 singleton births in Tehran. Data from the Iranian Maternal and Neonatal Network and the Maternal Vaccination Registry were analyzed for adverse outcomes like preterm birth and stillbirth using logistic regression. Of the births, 13.5% were vaccinated with Sinopharm. Results showed that vaccination significantly reduced the incidence of preterm birth, extremely preterm birth, and stillbirth, although first-trimester vaccination increased the risk of preterm birth. No increased risk was found for other adverse outcomes. The study concluded that Sinopharm vaccination during the second and third trimesters did not lead to adverse pregnancy outcomes and generally reduced the risk of such outcomes compared to unvaccinated individuals, while first-trimester vaccination was linked to a higher risk of preterm birth.
References :
Hatami, D., Habibelahi, A., Changizi, N. et al. Perinatal outcomes and sinopharm BBIBP-CorV vaccination during pregnancy. BMC Pregnancy Childbirth 24, 190 (2024). https://doi.org/10.1186/s12884-024-06389-z
https://bmcpregnancychildbirth.biomedcentral.com/articles/10.1186/s12884-024-06389-z
